APGE earnings analysis
What we found in APGE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing presents a well-funded but still loss-making clinical-stage biotechnology company, with $1.3 billion of cash, cash equivalents and marketable securities as of June 30, 2026, but a $160.0 million six-month net loss and $721.7 million accumulated deficit. Merger-related regulatory progress is positive, although the transaction remains subject to additional conditions and carries a potential $381.3 million termination fee. No revenue, EPS, margin, cash-flow, segment, or formal quantitative guidance data were disclosed in the provided filing text.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $1.3B liquidity position
- Cash, cash equivalents, and short- and long-term marketable securities totaled $1.3 billion as of June 30, 2026, providing substantial liquidity for ongoing operations.
- Several merger approvals completed
- The HSR waiting period expired on August 5, 2026, satisfying one condition to completion of the Merger; German clearance was unconditional and the Austrian Phase 1 review period expired on August 4, 2026.
- Pipeline investment continues
- Management reported a net loss of $160.0 million for the six months ended June 30, 2026 and an accumulated deficit of $721.7 million, underscoring the company’s continued investment in its clinical pipeline.
- Controls remained effective
- Disclosure controls and procedures were concluded effective as of June 30, 2026, and the company reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Merger closing and termination risk
- Completion of the pending Merger remains uncertain: the ACCC Phase 1 statutory review period is scheduled to expire on September 7, 2026, unless terminated earlier, and other customary closing conditions remain outstanding. If specified termination circumstances occur, Apogee could owe a $381,273,716 termination fee.
- Revenue-share obligations
- The May 2026 Revenue Share Agreement provided $100.0 million at signing and made available up to $700.0 million of additional milestone payments, but those milestones depend on registrational Phase 3 trials and FDA approval by December 31, 2030. Consummation of the Merger would also trigger change-of-control payment obligations to BXLS.
- Foreign and sole-source supply risk
- The company relies on foreign contract manufacturers and disclosed a March 2026 Samsung Biologics labor-union strike vote. Apogee also has sole-source supply relationships for APG990, APG333, and APG808 drug substance and drug product, creating potential clinical-supply disruption risk.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the filing. The filing discusses the pending Merger and related conditions, but does not provide a formal operating outlook.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Apogee Therapeutics reported a net loss of $74.1 million for Q1 2026, an increase from a net loss of $55.3 million in Q1 2025. The company continues to operate without disclosing revenue figures, but increased R&D…
- 10-K · March 2, 2026
- Apogee is a clinical-stage I&I-focused biotech advancing multiple engineered antibody programs (zumilokibart/APG777, APG279, APG273, APG808) with four validated targets. The company entered 2026 with a strong liquidity…
- 10-Q · November 10, 2025
- Apogee reported a GAAP net loss of $65,021,000 for Q3 (three months ended September 30, 2025), or GAAP diluted EPS of -$1.11, compared with a loss of $49,018,000, or EPS -$0.86 in the year-ago quarter. Operating…
- 10-Q · May 12, 2025
- Apogee Therapeutics reported a net loss of $55.3 million for Q1 2025, with diluted EPS of -$0.95, widening compared to a net loss of $32.1 million and EPS of -$0.64 a year earlier. The company had no reported revenue,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing APGE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever